International Clinical Trial: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729475) titled 'A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovascular Events' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Condition: Elevated Lipoprotein(a)

Intervention: Drug: SAL0137 Dose 1 Drug: SAL0137 Dose 2 Drug: SAL0137 Dose 3

Recruitment Status: Not recruiting

Phase: Phase 2

Date of F...